Product Description: FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Qingsong Guo, et al. FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28;23(10):1367–1377.
Molecular Weight: N/A
Research Area: Cancer
Target: Antibody-Drug Conjugates (ADCs)